A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma

The efficacy of melphalan (MEL) 140 mg/m(2) pre-transplant conditioning versus MEL 200 mg/m(2) for the elderly is still debated. We hypothesized that single-agent intravenous busulfan (BU) would show significant anti-myeloma efficacy and be better tolerated by elderly patients. A prospective 3+3 dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Radhakrishnan, Sabarinath V., Boyer, Michael, Sherwin, Catherine M., Zangari, Maurizio, Tricot, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923548/
https://www.ncbi.nlm.nih.gov/pubmed/31619057
http://dx.doi.org/10.1177/0963689719880541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923548/
https://www.ncbi.nlm.nih.gov/pubmed/31619057
http://dx.doi.org/10.1177/0963689719880541

Ejemplares similares